Heart Rhythm O2, published by Elsevier and indexed under ISSN 2666-5018, is a premier Open Access journal that has established itself as a vital platform for the dissemination of innovative research in Cardiology and Cardiovascular Medicine. Since its inception in 2020, this journal has rapidly gained recognition, achieving a distinguished Q1 ranking in its field as of 2023, underscoring its commitment to excellence and quality. Operating from its base in the Netherlands, Heart Rhythm O2 aims to bridge the gap between clinical practice and emerging scientific findings, fostering collaboration among researchers, healthcare professionals, and students globally. With a focus on high-impact original research, review articles, and clinical studies, the journal is dedicated to advancing our understanding of cardiac rhythm management and cardiovascular health. With open access options, it ensures that vital knowledge is freely available, facilitating the ongoing education and engagement of the medical community worldwide.

HEART RHYTHM is a leading academic journal published by Elsevier Science Inc, focusing on cutting-edge research in the field of cardiology and cardiovascular medicine. Established in 2004 and continuing its impactful journey through 2024, this journal holds an esteemed position within the academic community, boasting a 2023 Q1 ranking in both Cardiology and Cardiovascular Medicine and Medical Physiology, indicating its significant influence and contribution to these areas of study. With a commendable Scopus ranking—ranked #34 out of 387 in Cardiology and #11 out of 113 in Physiology—HEART RHYTHM is recognized for publishing high-quality research that drives advancements in understanding heart rhythms and associated medical conditions. Although it does not support open access, the journal remains accessible to professionals, researchers, and students, serving as a vital resource for the latest findings and theories in cardiovascular health. Invested in the mission to enhance knowledge and improve clinical practices, HEART RHYTHM stands as an essential publication for those aspiring to excel in the fields of cardiology and cardiovascular research.

Journal of Cardiology, published by ELSEVIER, stands as a prominent resource in the field of cardiology and cardiovascular medicine. With a rich history since its inception in 1987, this peer-reviewed journal aims to disseminate cutting-edge research that enhances the understanding and treatment of cardiovascular diseases. Its 2023 ranking places it in the Q2 category within its discipline, reflecting its significance and impact, as evidenced by a Scopus rank of #123 out of 387 journals, positioning it in the 68th percentile of its field. The journal is headquartered in Japan, providing a unique perspective on cardiological advances relevant not only to the Asian continent but also globally. Though it does not currently offer open access, the Journal of Cardiology remains a vital institutional resource for researchers, clinicians, and students seeking to push the boundaries of cardiovascular science and improve patient outcomes.

Cardiogenetics, published by MDPI, is a leading open-access journal dedicated to advancing the field of genetics as it pertains to cardiovascular health and diseases. Since its launch in 2011, this journal has been at the forefront of disseminating high-quality research that explores the genetic underpinnings of cardiovascular conditions, offering a platform for innovative studies, reviews, and case reports. With an ISSN of 2035-8253 and an E-ISSN of 2035-8148, Cardiogenetics aims to bridge the gap between genetic research and clinical application, helping researchers, healthcare professionals, and students stay abreast of the latest advancements and findings. The journal’s commitment to open access ensures that its valuable content is available to a global audience, fostering greater collaboration and knowledge sharing in the cardiovascular genetics community. By contributing to this dynamic field, Cardiogenetics plays a crucial role in improving patient outcomes and paving the way for personalized medicine in cardiology.

The Journal of Vascular Surgery-Venous and Lymphatic Disorders, published by Elsevier, is a distinguished peer-reviewed journal dedicated to advancing the knowledge and practice of vascular surgery with a particular focus on venous and lymphatic conditions. With an ISSN of 2213-333X and a robust impact factor, this journal ranks Q2 in Cardiology and Cardiovascular Medicine and Q1 in Surgery, reflecting its high relevance and contribution to the field. Covering a wide spectrum of topics from innovative surgical techniques to the latest developments in venous and lymphatic disorders, the journal serves as a vital resource for researchers, clinicians, and students alike. It not only disseminates cutting-edge research but also promotes best practices and interdisciplinary collaboration within the cardiovascular domain. The journal is accessible to a global audience, ensuring that impactful findings reach practitioners and researchers everywhere, further elevating the standards of patient care and surgical excellence.

Korean Circulation Journal, published by the Korean Society of Cardiology, has established itself as a prominent platform for disseminating research in the fields of Cardiology and Cardiovascular Medicine. With an ISSN of 1738-5520 and an E-ISSN of 1738-5555, this journal has been at the forefront of cardiovascular science since its inception in 2006 and is projected to continue until 2024. The journal's commitment to quality is reflected in its 2023 category quartiles, ranking in the second quartile (Q2) for both Cardiology and Internal Medicine, as well as its commendable Scopus rankings within the respective fields. Located in South Korea, the journal aims to bridge the gap between cutting-edge research and practical applications, serving as an invaluable resource for researchers, healthcare professionals, and students keen on advancing their understanding of cardiovascular health. Although currently not an open-access journal, it provides a wealth of knowledge that encourages evidence-based practice in clinical settings.

EUROPACE, published by Oxford University Press, stands at the forefront of cardiovascular and physiological research, as evidenced by its prestigious Q1 categorization in both Cardiology and Cardiovascular Medicine and Physiology (medical) for 2023. With an impressive ranking of #39 out of 387 and #14 out of 113 in the relevant Scopus categories, EUROPACE is recognized for its rigorous peer-reviewed articles that significantly contribute to advancing knowledge in heart rhythm disorders and related approaches. The journal has been operational since 1999 and will continue shaping the future of cardiovascular research until 2024, making it a vital resource for researchers, clinicians, and students alike. Through its commitment to disseminating high-quality research, EUROPACE plays a crucial role in enhancing the understanding and treatment of cardiac conditions, thereby influencing clinical practice and improving patient outcomes across the globe.

ACTA CARDIOLOGICA is a distinguished journal published by TAYLOR & FRANCIS LTD, focusing on the dynamic fields of Cardiology and Cardiovascular Medicine. Established in 1946, the journal has maintained a significant presence in the academic community, providing a platform for cutting-edge research and clinical studies that aim to address challenges in cardiovascular health. With its Q3 rating in both Cardiology and General Medicine categories, it showcases a robust compilation of articles that reflect the evolving landscape of cardiac care. Although ACTA CARDIOLOGICA is not an Open Access journal, it continues to serve a vital role for researchers, professionals, and students dedicated to advancing knowledge in cardiovascular health. This journal, with an ISSN of 0001-5385 and E-ISSN of 1784-973X, is a critical resource for those looking to stay updated on the latest developments and practices in the specialization, contributing significantly to the field until 2024 and beyond.

Cardiovascular Innovations and Applications is a premier open-access journal dedicated to advancing knowledge in the field of cardiovascular medicine. Published by COMPUSCRIPT since 2016, this journal provides a platform for the dissemination of innovative research and applications that address crucial topics in cardiology, aiming to bridge the gap between clinical practice and cutting-edge research. With an ISSN of 2009-8618 and an E-ISSN of 2009-8782, it operates on a global scale, facilitating access to high-quality content without financial barriers. The journal is positioned within the Medicine - Cardiology and Cardiovascular Medicine category, and its current Scopus rank of #321/387 reflects its potential for growth and influence in the academic community, being in the 17th percentile. Researchers, healthcare professionals, and students will find Cardiovascular Innovations and Applications an invaluable resource in their quest for the latest findings and advancements in cardiovascular health and treatment methodologies.

INTERNATIONAL JOURNAL OF HYPERTHERMIA, published by Taylor & Francis Ltd, is a leading peer-reviewed journal dedicated to advancing the field of hyperthermia and its applications in medical science, particularly within cancer research and related disciplines. With an ISSN of 0265-6736 and an E-ISSN of 1464-5157, this journal has been a vital resource since its establishment in 1985, offering a platform for innovative research and clinical applications aimed at improving treatment outcomes. The journal is recognized with a Q2 category ranking in several fields, including Cancer Research and Physiological Medicine, reflecting its significant contribution to scientific knowledge and clinical practices. Furthermore, it has been Open Access since 2019, ensuring that cutting-edge research is accessible to a global audience. By facilitating the exchange of ideas and fostering collaborations among researchers, professionals, and students, the INTERNATIONAL JOURNAL OF HYPERTHERMIA serves as an essential resource in the quest to exploit hyperthermia’s full potential in therapeutic settings.